Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kent Lucas

Internal Medicine New Bern, NC Medical Doctor

NPI 1619923836 CMS profile 163660

702 Newman Rd, New Bern, NC 28562

Open in the dashboard

General payments

$4,841

295 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,032 paid to institutions, not to them · program years 2020–2021

Through program year 2025, Kent Lucas of New Bern, NC is reported in the CMS Open Payments database as having received $4,841 across 295 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $16,032 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $847 50
2024 General $931 54
2023 General $1,045 57
2022 General $715 43
2021 General $455 35
2020 General $275 19
2019 General $574 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kent Lucas
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kent Lucas were reported at $847. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kent Lucas Internal Medicine median Middle half National median
2019 $574 $159 $48–$570 $163
2020 $275 $119 $33–$402 $114
2021 $455 $135 $37–$521 $132
2022 $715 $141 $42–$496 $149
2023 $1,045 $149 $45–$519 $160
2024 $931 $154 $47–$537 $164
2025 $847 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $478 40 payments
  2. GlaxoSmithKline, LLC. $470 33 payments
  3. AbbVie, Inc. $362 18 payments
  4. Novo Nordisk Inc $239 15 payments
  5. Lundbeck LLC $220 9 payments
  6. Actelion Pharmaceuticals US, Inc. $215 11 payments
  7. Astellas Pharma US Inc $208 11 payments
  8. Janssen Biotech, Inc. $181 11 payments
  9. Amgen Inc. $174 12 payments
  10. Grifols USA, LLC $137 7 payments
  11. Other $2,158 128 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,741 294 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $411 29 payments
  2. FreeStyle Libre 2 $398 33 payments
  3. OPSUMIT $215 11 payments
  4. VYEPTI $184 7 payments
  5. SIMPONI ARIA $168 10 payments
  6. Ozempic $164 11 payments
  7. Prolia $120 8 payments
  8. SKYRIZI $112 4 payments
  9. Prolastin-C Liquid $110 6 payments
  10. TREMFYA $109 6 payments
  11. Other $3,350 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 210 drugs

Part D claims

21,941

Median for Internal Medicine: 777

Drug cost

$2,541,168

Median for Internal Medicine: $73,373

Branded share of claims

29.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 268 $355,261
Jardiance Empagliflozin Brand 217 $209,779
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 676 $195,994
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 777 $162,657
Eliquis Apixaban Brand 166 $149,793
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 410 $120,795
Rybelsus Semaglutide Brand 64 $115,845
Mounjaro Tirzepatide Brand 90 $114,413
Farxiga Dapagliflozin Propanediol Brand 106 $105,682
Trulicity Dulaglutide Brand 80 $101,274

The 10 drugs with the highest cost, of 210 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 164 billing codes

Paid by Medicare

$653,634

Of which drugs: $364,916

Medicare patients

1,459

Average age 76

Services billed

52,008

786 women, 673 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 36%
Ischemic heart disease 35%
Chronic kidney disease 35%
Depression 31%
Atrial fibrillation 27%
Heart failure 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 41 3,060 $62,140
Vaccine for influenza for injection into muscle 90662 Office 288 288 $23,534
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 12 890 $22,227
Sarscv2 vac 30mcg trs-suc im 91320 Office 71 71 $10,531
Pcv20 vaccine im 90677 Office 29 29 $8,461
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 Office 13 7,650 $2,023
Injection, zoledronic acid, 1 mg J3489 Office 88 440 $1,707
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 21 21 $424

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $112
$112 — —
VYEPTI
  • Lundbeck LLC $108
$108 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $62
$62 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $51
$51 — —
BAFIERTAM
  • Banner Life Sciences, LLC $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record